Skip to main content

Table 1 Baseline characteristics of the study patients

From: The effect of cardiac shock wave therapy on myocardial function and perfusion in the randomized, triple-blind, sham-procedure controlled study

Variable OMT + CSWT group (n = 30) OMT + sham procedure group (n = 29) P value
Demographic characteristics
 Age, years 67.2 ± 7.8 69.4 ± 7.8 0.274
 Male sex, n (%) 19 (63.3) 26 (89.7) 0.018
Cardiovascular risk factors
 Hyperlipidaemia, n (%) 30 (100) 29 (100)
 Hypertension, n (%) 29 (96.7) 29 (100)
 Diabetes, n (%) 8 (26.7) 8 (27.6) 0.937
 Peripheral vascular disease, n (%) 10 (33.3) 12 (41.4) 0.523
 Current smoker, n (%) 1 (3.3) 4 (13.8) 0.195
 Positive family history for CVD, n (%) 10 (33.3) 19 (5.5) 0.013
Medical history
 Previous myocardial infarction, n (%) 15 (50.0) 23 (79.3) 0.019
 Previous percutaneous intervention, n (%) 16 (53.3) 15 (51.7) 0.902
 Previous CABG, n (%) 20 (66.7) 18 (62.1) 0.712
 No revascularization, n (%) 7 (23.3) 7 (24.1) 0.936
 Three-vessel disease, n (%) 24 (80.0) 22 (75.9) 0.161
 Two-vessel disease, n (%) 5 (16.7) 2 (6.9)
Clinical parameters
 Body mass index, kg/m2 30.0 ± 4.3 30.3 ± 3.8 0.755
 Angina episodes/week, median (25%;75%) 5.5 (3.3; 14.8) 7 (3.8; 15) 0.500
 Nitroglycerine consumption (times/week), median (25%;75%) 2 (1; 2) 2 (0; 5) 0.250
 Left ventricular ejection fraction (echocardiographic), % 54.4 ± 9.5 56.0 ± 7.2 0.366
 Systolic blood pressure, mmHg 124.7 ± 20.9 128.1 ± 22.1 0.845
Diastolic blood pressure, mmHg 81.1 ± 11.3 77.0 ± 11.2 0.341
Angina CCS class
 II, n (%) 8 (26.7) 9 (31.0) 0.711
 III, n (%) 22 (73.3) 20 (69.0)
Medical treatment
 ACE inhibitors / ARB, n (%) 30 (100) 29 (100)
 Beta-blocker, n (%) 28 (93.1) 27 (93.1) 1
 Long acting nitrates, n (%) 19 (63.3) 15 (51.7) 0.367
 Calcium channel blocker, n (%) 16 (51.3) 15 (51.7) 0.902
 Trimetazidine, n (%) 20 (66.7) 15 (51.7) 0.243
 Statins, n (%) 30 (100) 29 (100)
 Mean dose of atorvastatin, mg 36.2 ± 11.8a 40.3 ± 17.0 0.286
 Antiplatelets, n (%) 30 (100) 29 (100)
 Dual-antiplatelet therapy, n (%) 4 (13.3) 11 (37.9) 0.031
 Oral anti-diabetics, n (%) 4 (13.3) 7 (24.1) 0.287
ECG Exercise test
 Exercise duration, sec 350.1 ± 133.1 370.4 ± 131.0 0.558
  1. CABG Coronary artery bypass grafting, CCS Canadian Cardiovascular Society, CSWT Cardiac shock wave therapy, CVD cardiovascular disease, OMT optimal medical therapy, SAQ Seattle Angina Questionnaire
  2. aone patient in this group was on fluvastatin 80 mg, not included in mean dose calculations